News NIH abandons trial of SIGA's mpox drug Another clinical trial has found that SIGA Technologies' antiviral drug TPOXX (tecovirimat) is ineffective as a treatment for mpox.
News MSD gets first positive trial of Keytruda/Lynparza combo After a string of trial failures, MSD claims a partial win for Keytruda and Lynparza in advanced epithelial ovarian cancer.
News ASH: Blenrep ups survival by 42% in multiple myeloma trial GSK reveals the survival data that it reckons could return BCMA drug Blenrep to the forefront of multiple myeloma treatment.
News Fresh from IPO, obesity drug developer BioAge hits a hurdle Liver safety signal leads BioAge to discontinue its phase 2 trial of obesity candidate azelaprag, hitting the Nasdaq debutante's share price.
News ASH: Regeneron plays its PNH hand Regeneron's Alnylam-partnered poze-cemdi combination achieves greater disease control measured using LDH than AZ's market-leading Ultomiris.
News ASH: MSD’s ROR1 drug hits the target in first-line lymphoma The results of a phase 2 trial of MSD’s anti-ROR1 ADC zilovertamab vedotin back up the company's decision to start a phase 3 trial in DLBCL.
News J&J's oral IL-23 drug backed for psoriasis in EU J&J's oral psoriasis drug Icotyde heads up the list of new therapies recommended for EU approval at the CHMP's July meeting.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
